Prostaglandin E1 does not accelerate rTPA-induced thrombolysis in acute myocardial infarction.

[1]  R. Califf,et al.  Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. , 1993, Journal of the American College of Cardiology.

[2]  Eric J. Topol,et al.  A Randomized Trial of Late Reperfusion Therapy for Acute Myocardial Infarction , 1992, Circulation.

[3]  G. FitzGerald,et al.  Pharmacokinetics of Tissue‐Type Plasminogen Activator During Acute Myocardial Infarction in Men: Effect of a Prostacyclin Analogue , 1992, Circulation.

[4]  W. Cawello,et al.  On the metabolism of prostaglandin E1 administered intravenously to human volunteers. , 1991, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[5]  J. Schneider.  Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of saruplase (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi. , 1991, Prostaglandins.

[6]  R. Haslam,et al.  Effects of Nitrovasodilators on Platelet Cyclic Nucleotide Levels in Rabbit Blood; Role for Cyclic AMP in Synergistic Inhibition of Platelet Function by SIN‐1 and Prostaglandin E1 , 1991, Journal of cardiovascular pharmacology.

[7]  E. Braunwald,et al.  Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. , 1990, The American journal of cardiology.

[8]  J. Gore,et al.  Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. , 1990, Circulation.

[9]  J. Vane,et al.  Synergistic effect of prostaglandin E1 and isosorbide dinitrate in peripheral vascular disease , 1990, The Lancet.

[10]  J. Mehta,et al.  Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. , 1990, Circulation.

[11]  G. FitzGerald,et al.  Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. , 1989, Circulation.

[12]  K. Lee,et al.  Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. , 1989, Journal of the American College of Cardiology.

[13]  M. Kroll,et al.  Biochemical mechanisms of platelet activation. , 1989, Blood.

[14]  G. FitzGerald,et al.  Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. , 1989, Circulation research.

[15]  W. Schumacher,et al.  Effect of Thromboxane Antagonism on Recanalization During Streptokinase-Induced Thrombolysis in Anesthetized Monkeys , 1989, Journal of cardiovascular pharmacology.

[16]  W. Terres,et al.  Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis. , 1989, Circulation.

[17]  J. Loscalzo,et al.  PGE1 accelerates thrombolysis by tissue plasminogen activator. , 1989, Blood.

[18]  R. O'brien,et al.  Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis. , 1989, Circulation.

[19]  R. Feldman,et al.  Hemodynamic and angiographic effects of prostaglandin E1 in coronary artery disease. , 1988, The American journal of cardiology.

[20]  H. Sinzinger,et al.  Comparable effect of prostaglandin E1 in decreasing in vivo platelet deposition on human lesion sites after intravenous and intraarterial application. , 1988, Thrombosis research.

[21]  P. J. Simpson,et al.  Reduction of experimental canine myocardial infarct size with prostaglandin E1: inhibition of neutrophil migration and activation. , 1988, The Journal of pharmacology and experimental therapeutics.

[22]  Gundu H.R. Pao.  Influence of anti-platelet drugs on platelet-vessel waif interacticnks , 1987 .

[23]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[24]  K. Swedberg,et al.  Central haemodynamic and antiplatelet effects of iloprost--a new prostacyclin analogue--in acute myocardial infarction in man. , 1987, European heart journal.

[25]  C. Fisher,et al.  Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function. , 1987, The Journal of laboratory and clinical medicine.

[26]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[27]  R. Wyeth,et al.  Intracoronary prostaglandin E1 plus streptokinase in acute myocardial infarction. , 1986, The American journal of cardiology.

[28]  D. Collen,et al.  Assay of Human Tissue-Type Plasminogen Activator (t-PA) with an Enzyme-Linked Immunosorbent Assay (ELISA) Based on Three Murine Monoclonal Antibodies to t-PA , 1985, Thrombosis and Haemostasis.

[29]  M J Davies,et al.  Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. , 1984, The New England journal of medicine.

[30]  H. Pickles,et al.  Epoprostenol (prostacyclin,PGI2) increases apparent liver blood flow in man. , 1983, Prostaglandins, leukotrienes, and medicine.

[31]  J. Mustard,et al.  Inhibitors of ADP-induced platelet aggregation prevent fibrinogen binding to rabbit platelets and cause rapid deaggregation and dissociation of bound fibrinogen. , 1981, The Journal of laboratory and clinical medicine.

[32]  E. D. Jacobson,et al.  Superior mesenteric angiography and blood flow measurement following intra-arterial injection of prostaglandin E1. , 1980, Radiology.

[33]  J. Westwick.  The effect of pulmonary metabolites of prostaglandins E1, E2 and F2alpha on ADP-induced aggregation of human and rabbit platelets [proceedings]. , 1976, British journal of pharmacology.

[34]  R. Horton,et al.  Metabolism of prostaglandins A1 and E1 in man. , 1975, The Journal of clinical investigation.

[35]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .

[36]  J. Smith,et al.  The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets. , 1971, The Biochemical journal.

[37]  G. Ball,et al.  Effect of prostaglandin E1 alone and in combination with theophylline or aspirin on collagen-induced platelet aggregation and on platelet nucleotides including adenosine 3′:5′-cyclic monophosphate , 1970 .

[38]  A. Fletcher,et al.  Enzymic lysis of plasma clots: The influence of fibrin stabilization on lysis rates , 1967 .

[39]  A. J. Honour,et al.  Effect of prostaglandin E1 on platelet behaviour in vitro and in vivo. , 1967, British medical journal.

[40]  M. Friedman,et al.  The pathogenesis of a coronary thrombus. , 1966, The American journal of pathology.

[41]  K. Lindahl-Kiessling,et al.  USE AND ABUSE OF ELECTROENCEPHALOGRAPHY. , 1964, Lancet.